| scholarly article | Q13442814 |
| P50 | author | Jay D Horton | Q89378224 |
| P2093 | author name string | Chai-Wan Kim | |
| Cai Li | |||
| Shawn C Burgess | |||
| Stuart Milstein | |||
| Kevin Fitzgerald | |||
| Stanislaw Deja | |||
| David E Kelley | |||
| Xiaorong Fu | |||
| Carol Addy | |||
| Jun Kusunoki | |||
| Manu Chakravarthy | |||
| Marcie Ruddy | |||
| Norma N Anderson | |||
| Steve Previs | |||
| P2860 | cites work | The subcellular localization of acetyl-CoA carboxylase 2 | Q22253198 |
| Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade | Q24336608 | ||
| Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal | Q24529830 | ||
| Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake | Q24622227 | ||
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 | ||
| Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis | Q24631468 | ||
| Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates | Q24646644 | ||
| Identification of a physiologically relevant endogenous ligand for PPARalpha in liver | Q24653691 | ||
| Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets | Q24683319 | ||
| Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2 | Q28209958 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology | Q28267844 | ||
| SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation | Q28365331 | ||
| Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice | Q28589371 | ||
| SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver | Q29547646 | ||
| Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease | Q29614897 | ||
| Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity | Q29614932 | ||
| Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q29615691 | ||
| Molecular mediators of hepatic steatosis and liver injury | Q29616709 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action | Q33641569 | ||
| De novo lipogenesis in humans: metabolic and regulatory aspects | Q33655979 | ||
| A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis | Q33673834 | ||
| A feed-forward loop amplifies nutritional regulation of PNPLA3 | Q33842841 | ||
| Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL | Q33849024 | ||
| Hepatic and whole-body fat synthesis in humans during carbohydrate overfeeding | Q34427952 | ||
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
| Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis | Q34675058 | ||
| Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis | Q35039363 | ||
| Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers | Q35534139 | ||
| Human fatty liver disease: old questions and new insights | Q35588477 | ||
| Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity | Q36082167 | ||
| Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up st | Q36205001 | ||
| Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis | Q36291761 | ||
| Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis | Q36357941 | ||
| Plasma PCSK9 preferentially reduces liver LDL receptors in mice | Q36662650 | ||
| Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes | Q36698641 | ||
| Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. | Q36770743 | ||
| The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals | Q36869039 | ||
| Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice | Q37089101 | ||
| Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. | Q37250895 | ||
| Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a | Q37360326 | ||
| Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells | Q37364195 | ||
| Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus | Q38319698 | ||
| Regulation of hepatic de novo lipogenesis in humans | Q41138438 | ||
| Metabolic interactions between glucose and fatty acids in humans | Q41719034 | ||
| Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging | Q43815610 | ||
| Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c | Q43848640 | ||
| A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone | Q43937023 | ||
| Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes | Q44452988 | ||
| A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis | Q44749300 | ||
| "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis | Q46626411 | ||
| Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | Q47765250 | ||
| Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD). | Q50236536 | ||
| Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. | Q51330295 | ||
| Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. | Q51557334 | ||
| Regulation of acetyl-coenzyme A carboxylase. II. Effect of fasting and refeeding on the activity, phosphate content, and aggregation state of the enzyme. | Q51625556 | ||
| Regulation of acetyl-coenzyme A carboxylase. I. Purification and properties of two forms of acetyl-coenzyme A carboxylase from rat liver | Q69916715 | ||
| Quantification of malonyl-coenzyme A in tissue specimens by high-performance liquid chromatography/mass spectrometry | Q82871562 | ||
| A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease | Q95000126 | ||
| P433 | issue | 2 | |
| P921 | main subject | triglyceride | Q186319 |
| steatosis | Q1365091 | ||
| P304 | page(s) | 394-406.e6 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Cell Metabolism | Q1254684 |
| P1476 | title | Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. | |
| P478 | volume | 26 |
| Q92342120 | AMP-activated protein kinase: the current landscape for drug development |
| Q92995916 | Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis |
| Q55364368 | Activation of AMPK for a Break in Hepatic Lipid Accumulation and Circulating Cholesterol. |
| Q64080416 | Capsaicin Targets Lipogenesis in HepG2 Cells Through AMPK Activation, AKT Inhibition and PPARs Regulation |
| Q90417214 | Cellular and molecular effects of silymarin on the transdifferentiation processes of LX-2 cells and its connection with lipid metabolism |
| Q92267409 | Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH |
| Q90227551 | Curcumin supplementation mitigates NASH development and progression in female Wistar rats |
| Q89945654 | Developmental changes in hepatic lipid metabolism of chicks during the embryonic periods and the first week of posthatch |
| Q90438587 | Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins |
| Q92105294 | Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate |
| Q100994709 | Drug discovery and treatment paradigms in nonalcoholic steatohepatitis |
| Q92970029 | Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis |
| Q90825396 | First-in-class fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities |
| Q90612995 | GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease |
| Q61451626 | Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD |
| Q92092761 | Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance |
| Q55506426 | Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease. |
| Q90113523 | Hepatoprotective Effects of Steamed and Freeze-Dried Mature Silkworm Larval Powder against Ethanol-Induced Fatty Liver Disease in Rats |
| Q90229814 | Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver |
| Q92783864 | Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH |
| Q99562197 | Liver Pyruvate Kinase Promotes NAFLD/NASH in both Mice and Humans in a Sex-Specific Manner |
| Q92454573 | Lycopene Modulates Pathophysiological Processes of Non-Alcoholic Fatty Liver Disease in Obese Rats |
| Q59443140 | Mechanisms of NAFLD development and therapeutic strategies. |
| Q102144617 | Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis |
| Q64077761 | Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship |
| Q89742823 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study |
| Q92177891 | The Administration of Chitosan-Tripolyphosphate-DNA Nanoparticles to Express Exogenous SREBP1a Enhances Conversion of Dietary Carbohydrates into Lipids in the Liver of Sparus aurata |
| Q58801216 | The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain |
Search more.